Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation
Background. Use of amiodarone (AMIO) in atrial fibrillation (AF) has significant side effects over prolonged periods. Wenxin Keli (WXKL), a Chinese herb extract, has been shown to be effective in atrial-selective inhibiting peak INa and hence beneficial in treating atrial arrhythmias, including atri...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2018/6047271 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548452089724928 |
|---|---|
| author | Nixiao Zhang Gary Tse Shristi Dahal Yajuan Yang Mengqi Gong Calista Zhuo Yi Chan Enzhao Liu Gang Xu Konstantinos P. Letsas Panagiotis Korantzopoulos Guangping Li Tong Liu |
| author_facet | Nixiao Zhang Gary Tse Shristi Dahal Yajuan Yang Mengqi Gong Calista Zhuo Yi Chan Enzhao Liu Gang Xu Konstantinos P. Letsas Panagiotis Korantzopoulos Guangping Li Tong Liu |
| author_sort | Nixiao Zhang |
| collection | DOAJ |
| description | Background. Use of amiodarone (AMIO) in atrial fibrillation (AF) has significant side effects over prolonged periods. Wenxin Keli (WXKL), a Chinese herb extract, has been shown to be effective in atrial-selective inhibiting peak INa and hence beneficial in treating atrial arrhythmias, including atrial fibrillation. The aim of this randomized controlled trial was to evaluate potential effects of AMIO plus WXKL on conversion rate and time in patients with recent-onset AF. Methods. A total of 41 patients (71 ± 12 years, 44% male) with recent-onset (<48 h) AF eligible for conversion were randomized to receive either intravenous amiodarone (loading dose 5 mg/kg in 1 hour followed by 50 mg/h; n=21) or amiodarone with same dosage plus oral WXKL 18 g thrice daily (n=20) for 24 hours. Results. Conversion rate at 24 hours was of no difference between the two groups (75.0% vs. 81.0%, P=0.72); however, conversion time was markedly shorter in the AMIO + WXKL group compared to the AMIO group (291 ± 235 minutes vs. 725 ± 475 minutes, P=0.003). There were no serious adverse events during the study. Conclusion. Administration of amiodarone plus WXKL for recent-onset AF conversion was safe and effective, with faster sinus rhythm restoration compared with amiodarone alone. |
| format | Article |
| id | doaj-art-2aa6ff7743f7409a87a360ab8c506507 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-2aa6ff7743f7409a87a360ab8c5065072025-02-03T06:14:01ZengWileyCardiology Research and Practice2090-80162090-05972018-01-01201810.1155/2018/60472716047271Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial FibrillationNixiao Zhang0Gary Tse1Shristi Dahal2Yajuan Yang3Mengqi Gong4Calista Zhuo Yi Chan5Enzhao Liu6Gang Xu7Konstantinos P. Letsas8Panagiotis Korantzopoulos9Guangping Li10Tong Liu11Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaDepartment of Medicine and Therapeutics, Chinese University of Hong Kong, Ma Liu Shui, Hong KongTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaDepartment of Medicine and Therapeutics, Chinese University of Hong Kong, Ma Liu Shui, Hong KongTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaSecond Department of Cardiology, Laboratory of Cardiac Electrophysiology, “Evangelismos” General Hospital of Athens, Athens, GreeceFirst Department of Cardiology, University of Ioannina Medical School, Stavrou Niarchou-1, 45221 Ioannina, GreeceTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaTianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, ChinaBackground. Use of amiodarone (AMIO) in atrial fibrillation (AF) has significant side effects over prolonged periods. Wenxin Keli (WXKL), a Chinese herb extract, has been shown to be effective in atrial-selective inhibiting peak INa and hence beneficial in treating atrial arrhythmias, including atrial fibrillation. The aim of this randomized controlled trial was to evaluate potential effects of AMIO plus WXKL on conversion rate and time in patients with recent-onset AF. Methods. A total of 41 patients (71 ± 12 years, 44% male) with recent-onset (<48 h) AF eligible for conversion were randomized to receive either intravenous amiodarone (loading dose 5 mg/kg in 1 hour followed by 50 mg/h; n=21) or amiodarone with same dosage plus oral WXKL 18 g thrice daily (n=20) for 24 hours. Results. Conversion rate at 24 hours was of no difference between the two groups (75.0% vs. 81.0%, P=0.72); however, conversion time was markedly shorter in the AMIO + WXKL group compared to the AMIO group (291 ± 235 minutes vs. 725 ± 475 minutes, P=0.003). There were no serious adverse events during the study. Conclusion. Administration of amiodarone plus WXKL for recent-onset AF conversion was safe and effective, with faster sinus rhythm restoration compared with amiodarone alone.http://dx.doi.org/10.1155/2018/6047271 |
| spellingShingle | Nixiao Zhang Gary Tse Shristi Dahal Yajuan Yang Mengqi Gong Calista Zhuo Yi Chan Enzhao Liu Gang Xu Konstantinos P. Letsas Panagiotis Korantzopoulos Guangping Li Tong Liu Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation Cardiology Research and Practice |
| title | Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation |
| title_full | Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation |
| title_fullStr | Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation |
| title_full_unstemmed | Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation |
| title_short | Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation |
| title_sort | efficacy of wenxin keli plus amiodarone versus amiodarone monotherapy in treating recent onset atrial fibrillation |
| url | http://dx.doi.org/10.1155/2018/6047271 |
| work_keys_str_mv | AT nixiaozhang efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT garytse efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT shristidahal efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT yajuanyang efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT mengqigong efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT calistazhuoyichan efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT enzhaoliu efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT gangxu efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT konstantinospletsas efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT panagiotiskorantzopoulos efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT guangpingli efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation AT tongliu efficacyofwenxinkeliplusamiodaroneversusamiodaronemonotherapyintreatingrecentonsetatrialfibrillation |